- Active, not recruiting
NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study
Updated: Jun 15, 2022
The CASTOR Trial
Dara Vd
DVd
NCT02136134: Phase 3: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor
Janssen Research & Development, LLC
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02136134
Official Title: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : May 12, 2014
Click here for details on ClinicalTrials.gov
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
PMID: 27557302 N Engl J Med; Aug 2016
Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor
Conclusions: In this updated analysis of CASTOR, D-Vd maintains significant PFS and ORR benefits in RRMM, with the greatest benefit achieved by pts who received 1 PL of therapy. The safety profile of D-Vd remains consistent with longer follow-up, with no new safety concerns reported. These data continue to suggest that administration of D-Vd to RRMM pts after first relapse may provide the greatest clinical benefit.
653.Myeloma: Therapy, excluding Transplantation| November 13, 2019
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
PMID: 32819447 J Hematol Oncol; Aug 2020
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
PMID: 31221782 Haematologica; Jan 2020
1655 Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison
Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I
Hematology Disease Topics & Pathways:
Diseases, Combinations, Lymphoid Malignancies
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Locations
United States, Alabama
United States, California
United States, Connecticut
United States, Florida
United States, Georgia
United States, Illinois
United States, Kansas
United States, Louisiana
United States, Massachusetts
United States, Michigan
United States, New York
United States, North Carolina
United States, Oregon
United States, Pennsylvania
United States, Rhode Island
United States, Washington
Mexico
Australia
South America
Brazil
Europe
Czechia
Netherlands
Poland
Spain
Sweden
Germany
Hungary
Turkey
Ukraine
Asia
Korea, Republic of
Russian Federation